Abstract
Purpose :
The aim of this study is to evaluate the efficacy of corneal crosslinking to maintain stability in patients with keratoconus treated at a referral center in central Mexico by determining the incidence of progression at 6 months of treatment.
Methods :
A retrospective analysis of patients treated with corneal crosslinking from 2016 to 2018 was done. The inclusion criteria were patients of any age that had a register of Scheimpflug imaging at baseline before and at 6 months after treatment. The data analyzed was: Kmax, central corneal thickness (CCT) and keratoconus vertex back (KVb). According to the Global Consensus on Keratoconus if two of these parameters changed, then, progression was determined. A change in each parameter was established if there was an increase of 1D in Kmax, a 2% decrease in thickness and/or any increase in KVb.
Results :
Patients were divided according to what technique was used: epithelium on or epithelium off. A total of 18 patients (19 eyes) were in the epithelium on group. Of these: 8 were female and 11 were males, and the mean age at time of treatment was 22.66 y.o. The mean Kmax at baseline was 57.91D and after treatment 57.45D, the mean CCT at baseline was 395.42 and after treatment 399.63, the mean KVb at baseline was 122.21 and 117.87 after treatment -10.52D. Of the 19 eyes treated, 5 eyes (26.31%) had progression. A total of 37 patients (60 eyes) were in the epithelium off group. Of these 13 were female and 24 were males, and the mean age at the time of treatment was 20.97 y.o. The mean Kmax at baseline was 54.11D and after treatment 54.31D, the mean CCT at baseline was 460.5 and after treatment 452.65, the mean KVb at baseline was 96.75D and after treatment 94.86. Of the 60 eyes treated, 15 eyes (25%) had progression
Conclusions :
The aim of treating keratoconus at early stages is to halt progression and preserve visual function. In this study the majority of the patients maintained stability, therefore corneal accelerated crosslinking might be effective in halting keratoconus progression in the Mexican population.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.